Exelixis
EXEL
#1647
Rank
A$18.97 B
Marketcap
A$75.48
Share price
-5.25%
Change (1 day)
31.26%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): A$4.67

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$4.46. In 2025 the company made an earnings per share (EPS) of A$4.11.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$4.6713.45%
2025A$4.11
2023A$0.9314.61%
2022A$0.81-22.97%
2021A$1.05100%
2020A$0.53-65.09%
2019A$1.51-53.91%
2018A$3.27333.96%
2017A$0.75-260.61%
2016A-$0.47-58.75%
2015A-$1.14-42.45%
2014A-$1.985.3%
2013A-$1.88

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$12.43 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.86-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$20.61 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$3.64-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$5.09 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$5.07 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$5.53 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$33.88-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.20-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA